Company: BGLC
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001477932-25-006023
Chunk: 24

Company: BioNexus Gene Lab Corp
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 1
Chunk 24
---
  (40,173)  (40,173)Add: Foreign translation differences  (92,156)  (186,004)Property, plant and equipment, net $1,592,907  $1,522,990  During the six month period ended June 30, 2025 and 2024, the Company recorded depreciation of $54,442 and $40,343, respectively. 

 19Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024 

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

NOTE 7 – INVESTMENTS IN EQUITY SECURITIES   As of   June 30,  December 31,   2025  2024 As of beginning of the period/year $1,265,166  $1,699,831 Addition during the period/year  -   492,732 Disposal during the period/year  -   (1,030,368)Fair value (loss)/gain  (91,243)  69,476 Foreign exchange translation   74,765   33,495 As of end of the period/year $1,248,688  $1,265,166  For the six month period ended June 30, 2025 and 2024, the net fair value (loss)/gains on the investments in equity securities were $(91,243) and $72,884 recorded in administrative expenses and other income of the Consolidated Statements of Operations and Comprehensive Income/(Loss).   The investments in equity securities consist of the following shares:       As of   June 30,  December 31,   2025  2024 Investment in equity securities with readily determined fair value (1):      Malaysia  836,662   863,810 Singapore  174,520   177,808   $1,011,182  $1,041,618          Investment in equity securities without readily determined fair value:        Malaysia  237,506   223,548   $1,